|Free Dividend Report|
|Stock Splits Calendar|
|RARE Stock Split History|
|Preferred Stock Newsletter|
|RARE Options Chain|
|Stock Message Boards|
Ultragenyx Pharmaceutical (RARE) has 2 splits in our RARE split history database. The first split for RARE took place on September 06, 2000. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. RARE's second split took place on September 03, 2003. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.
When a company such as Ultragenyx Pharmaceutical splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the RARE split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ultragenyx Pharmaceutical shares, starting with a $10,000 purchase of RARE, presented on a split-history-adjusted basis factoring in the complete RARE split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-0.84%|
|About Ultragenyx Pharmaceutical|
|Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia. According to our RARE split history records, Ultragenyx Pharmaceutical has had 2 splits.|
|RARE Split History Table|
|09/06/2000||3 for 2|
|09/03/2003||3 for 2|
|Healthcare Stock Splits|
|RARE is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: RARE shares outstanding history